Long non‐coding <i>PANDAR</i> as a novel biomarker in human cancer: A systematic review

Zou, Yanfen; Zhong, Yuting; Wu, Junjie; Xiao, Huizhong; Zhang, Xintao; Liao, Xin; Li, Jianfa; Mao, Xuhua; Liu, Yuchen; Zhang, Fuyou

doi:10.1111/cpr.12422

Cited by 46 publications

(26 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with our research, previous studies con rmed that some lncRNAs were signi cantly related to clinical traits of tumors. For example, Mahdi's research showed that there was a positive correlation between lncRNA and TNM stage [32]. Thus, we speculated that this prognostic signature can be used as a supplement to colon cancer TNM classi cation and staging.…”

Section: Discussionmentioning

confidence: 90%

An immune-related lncRNA signature as a prognostic immunotherapy target for colon cancer

Yao

Dong

et al. 2020

Preprint

View full text Add to dashboard Cite

Background：We aimed to investigate an immune-related long non-coding RNA (lncRNA) signature that may be exploited as a potential immunotherapy target in colon cancer. Materials and methods: Colon cancer samples from The Cancer Genome Atlas (TCGA) containing available clinical information and complete genomic mRNA expression data were used in our study. We then constructed immune-related lncRNA co-expression networks to identify the most promising immune-related lncRNAs. According to the risk score developed from screened immune-related lncRNAs, the high-risk and low-risk groups were separated on the basis of the median risk score, which served as the cutoff value. An overall survival analysis was then performed to confirm that the risk score developed from screened immune-related lncRNAs could predict colon cancer prognosis. The prediction reliability was further evaluated in the independent prognostic analysis and receiver operating characteristic curve (ROC). A principal component analysis (PCA) and gene set enrichment analysis (GSEA) were performed for functional annotation. Results: Information for a total of 514 patients was included in our study. After multiplex analysis, 12 immune-related lncRNAs were confirmed as a signature to evaluate the risk scores for each patient with cancer. Patients in the low-risk group exhibited a longer overall survival (OS) than those in the high-risk group. Additionally, the risk scores were an independent factor, and the Area Under Curve (AUC) of ROC for accuracy prediction was 0.726. Moreover, the low-risk and high-risk groups displayed different immune statuses based on principal components and gene set enrichment analysis.Conclusions: Our study suggested that the signature consisting of 12 immune-related lncRNAs can provide an accessible approach to measuring the prognosis of colon cancer and may serve as a valuable antitumor immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 90%

An immune-related lncRNA signature as a prognostic immunotherapy target for colon cancer

Yao

Dong

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Moreover, PANDA silencing results in cell cycle arrest in G1/ S transition through upregulation of cyclin-dependent kinase inhibitor p18 in U2OS osteosarcoma cell line. Depletion of PANDA leads to cell death of doxorubicin treated cells through upregulation of apoptotic activators APAF1, BIK, FAS, and LRDD [249,250]. Taken together, these findings imply that inhibition of PANDA might serve as a therapeutic intervention to induce cell cycle arrest and apoptosis in osteosarcoma.…”

Section: Lncrnas As Therapeutic Targets In Osteosarcomamentioning

confidence: 80%

Long Noncoding RNAs in Osteosarcoma: Mechanisms and Potential Clinical Implications

Valavanis¹,

Stanc²

2019

Osteosarcoma – Diagnosis, Mechanisms, and Translational Developments

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are noncoding transcripts consisting of a diverse class of long RNAs of more than 200 nucleotides in length. Recent studies have shown that lncRNAs are involved in cell signal transduction pathways, cell cycle and cell death regulation, chromatin remodeling, and gene expression regulation at the transcriptional and posttranscriptional levels. They are also involved in the metastatic process of different types of tumors, such as urothelial carcinoma, colon carcinoma, breast carcinoma, lung carcinoma, and hepatocellular carcinoma. In addition, lncRNAs demonstrate precise expression patterns in specific tissues and cells and therefore play important roles in cell differentiation and tissue development. In this chapter, we review the molecular mechanisms of lncRNA cell functions and their involvement in the pathogenesis, progression, and metastasis of osteosarcoma, a rare bone tumor of childhood and adolescence. We also review emerging clinical implications of lncRNA use as potential prognostic biomarkers and therapeutic targets, as well as their putative involvement in drug resistance, in osteosarcoma progression, and in therapeutic interventions.

show abstract

“…Indeed, potential diagnostic and prognostic biomarkers for NSCLC are increasingly being reported such as plasma linc00152 [ 20 ], circulating lncRNA PCAT6 [ 21 ], AFAP1-AS1 [ 22 ], HOTAIR [ 23 , 24 ], lncRNA 00312 and 00673 [ 25 ] for diagnosis, and lncRNA CASC9.5 [ 26 ] plus LINC00968 [ 27 ] for NSCLC prognosis. In addition, PANDAR [ 28 ] and LncRNA RP11 713B9.1 [ 29 ] were also described as promising biomarkers and potential therapeutic targets for NSCLC. Patients with NSCLC, advanced nonsquamous NSCLC, and squamous cell histology were suggested to test for EGFR mutations, ALK rearrangements, and ROS1 fusions [ 30 ].…”

Section: Introductionmentioning

confidence: 99%

Identification of lncRNA biomarkers for lung cancer through integrative cross-platform data analyses

Zhao

Khadka

Deng

2020

Aging

View full text Add to dashboard Cite

This study was designed to identify lncRNA biomarker candidates using lung cancer data from RNA-Seq and microarray platforms separately. Lung cancer datasets were obtained from the Gene Expression Omnibus (GEO, n = 287) and The Cancer Genome Atlas (TCGA, n = 216) repositories, only common lncRNAs were used. Differentially expressed (DE) lncRNAs in tumors with respect to normal were selected from the Affymetrix and TCGA datasets. A training model consisting of the top 20 DE Affymetrix lncRNAs was used for validation in the TCGA and Agilent datasets. A second similar training model was generated using the TCGA dataset. First, a model using the top 20 DE lncRNAs from Affymetrix for training and validated using TCGA and Agilent, achieved high prediction accuracy for both training (98.5% AUC for Affymetrix) and validation (99.2% AUC for TCGA and 92.8% AUC for Agilent). A similar model using the top 20 DE lncRNAs from TCGA for training and validated using Affymetrix and Agilent, also achieved high prediction accuracy for both training (97.7% AUC for TCGA) and validation (96.5% AUC for Affymetrix and 80.9% AUC for Agilent). Eight lncRNAs were found to be overlapped from these two lists.

show abstract

Long non‐coding PANDAR as a novel biomarker in human cancer: A systematic review

Cited by 46 publications

References 65 publications

An immune-related lncRNA signature as a prognostic immunotherapy target for colon cancer

An immune-related lncRNA signature as a prognostic immunotherapy target for colon cancer

Long Noncoding RNAs in Osteosarcoma: Mechanisms and Potential Clinical Implications

Identification of lncRNA biomarkers for lung cancer through integrative cross-platform data analyses

Contact Info

Product

Resources

About